Gregor Blank

Summary

Country: Germany

Publications

  1. ncbi request reprint Treatment of liver transplant graft-versus-host disease with antibodies against tumor necrosis factor-α
    Gregor Blank
    Department of General, Visceral and Transplant Surgery, University Hospital, Tubingen, Germany
    Exp Clin Transplant 11:68-71. 2013
  2. pmc Adenocarcinoma arising in a cystic duplication of the small bowel: case report and review of literature
    Gregor Blank
    Department of General, Visceral and Transplant Surgery, University of Tubingen, Hoppe Seyler Strasse 3, D 72076 Tubingen, Germany
    World J Surg Oncol 10:55. 2012
  3. doi request reprint Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo
    Gregor Blank
    Department of General, Visceral and Transplantation Surgery, University Hospital Tubingen, Tubingen, Germany
    Ann Hematol 94:1907-19. 2015

Detail Information

Publications3

  1. ncbi request reprint Treatment of liver transplant graft-versus-host disease with antibodies against tumor necrosis factor-α
    Gregor Blank
    Department of General, Visceral and Transplant Surgery, University Hospital, Tubingen, Germany
    Exp Clin Transplant 11:68-71. 2013
    ..A consensus for the treatment of graft-versus-host disease still is lacking, but tumor necrosis factor-α is an encouraging target for therapy to decrease the symptoms of graft-versus-host disease and enable mucosal regeneration...
  2. pmc Adenocarcinoma arising in a cystic duplication of the small bowel: case report and review of literature
    Gregor Blank
    Department of General, Visceral and Transplant Surgery, University of Tubingen, Hoppe Seyler Strasse 3, D 72076 Tubingen, Germany
    World J Surg Oncol 10:55. 2012
    ..Here we report a unique case of an adenocarcinoma arising in a coincidentally found cystic duplication of the small bowel...
  3. doi request reprint Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo
    Gregor Blank
    Department of General, Visceral and Transplantation Surgery, University Hospital Tubingen, Tubingen, Germany
    Ann Hematol 94:1907-19. 2015
    ..GZ-αβTCR's outstanding capacity to prevent GVHD and ameliorate an ongoing GVHD while sparing immune cells other than αβT cells strongly recommends GZ-αβTCR for the prevention and treatment of acute GVHD in clinical settings. ..